CeGaT has updated CancerPrecision®, CancerFusionRx®, and the Diagnostic Panel for Hereditary Tumor Diseases. The revised portfolio introduces more targeted testing options for hereditary tumor syndromes while expanding molecular tumor analysis.
More Targeted Testing for Hereditary Tumor Syndromes
Within the Diagnostic Panel for Hereditary Tumor Diseases, the former gene set Other Familial Tumor Diseases has been replaced by dedicated gene sets for Cowden syndrome, Li-Fraumeni syndrome, neurofibromatosis/schwannomatosis, and tuberous sclerosis. This allows you to select the gene set that best matches the suspected hereditary tumor syndrome.
For a more comprehensive diagnostic evaluation, the new CAN-all add-on extends the analysis to the complete panel for hereditary tumor diseases. It includes genes relevant for additional differential diagnoses as well as pathogenic and likely pathogenic secondary findings associated with other hereditary tumor risks.
The pediatric solid tumor gene set has also been expanded in accordance with the current S1 guideline on medulloblastoma.
Expanded Molecular Tumor Analysis
The molecular tumor diagnostics portfolio has also been enhanced. CancerPrecision® and CancerFusionRx® now include additional clinically relevant genes and gene fusions, such as ELOC alterations in renal cell carcinoma and CREM fusions in Ewing sarcoma. These updates support more precise molecular tumor classification and help inform treatment decisions.
We are happy to support you in selecting the most suitable diagnostic strategy for your patients. Call us at +49 (0) 7071 565 44 55 or email us at tumor@cegat.com.